Mitogen-activated protein kinases and their inhibitors: Friend or foe in fighting psoriasis?

Dermatology Research Focus on Acne, Melanoma and Psoriasis

Volumn , Issue , 2010, Pages 185-192

  Hsu, Stephen ^a   Dickinson, Douglas ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940235362     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (49)

1. Kastelan, M; Massari, LP; Brajac, I. Apoptosis mediated by cytolytic molecules might be responsible for maintenance of psoriatic plaques. Med Hypotheses., 2006, 67(2), 336-7.
2. Liu, Y; Krueger, JG; Bowcock, AM. Psoriasis: genetic associations and immune system changes. Genes Immun., 2006 Nov 9.
3. Ghoreschi, K; Rocken, M. Immunopathogenesis of psoriasis, J Dtsch Dermatol Ges., 2003 Jul, 1(7), 524-32.
4. Jones, DA; Yawalkar, N; Suh, KY; Sadat, S; Rich, B; Kupper, TS. Identification of autoantigens in psoriatic plaques using expression cloning. J Invest Dermatol., 2004 Jul, 123(1), 93-100.
5. Kostovic, K; Pasic, A. Phototherapy of psoriasis: review and update. Acta Dermatovenerol Croat., 2004, 12, 42-50.
6. Gasparro, FP. The role of PUVA in the treatment of psoriasis. Photobiology issues related to skin- cancer incidence. Am J Clin Dermatol, 2000, 1, 337-48.
7. Kim, AL; Labasi, JM; Zhu, Y; Tang, X; McClure, K; Gabel, CA; Athar, M; Bickers, DR. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol., 2005 Jun, 124(6), 1318-25.
8. Kim, JY; Oh, KN; Han, EH; Kim, DH; Jeong, TC; Lee, ES; Jeong, HG. Methoxychlor-induced inducible nitric oxide synthase and proinflammatory cytokines expression in macrophages via NF-kappaB, ERK, and p38 mitogen-activated protein kinases. Biochem Biophys Res Commun., 2005 Aug 12, 333(4), 1234-40.
9. Hughes-Fulford, M; Sugano, E; Schopper, T; Li, CF; Boonyaratanakornkit, JB; Cogoli, A. Early immune response and regulation of IL-2 receptor subunits. Cell Signal., 2005 Sep, 17(9), 1111-24.
10. Iwata, Y; Furuichi, K; Sakai, N; Yamauchi, H; Shinozaki, Y; Zhou, H; Kurokawa, Y; Toyama, T; Kitajima, S; Okumura, T; Yamada, S; Maruyama, I; Matsushima, K; Kaneko, S; Wada, T. Dendritic cells contribute to autoimmune kidney injury in MRL-Faslpr mice. J Rheumatol., 2009 Feb, 36(2), 306-14.
11. Berkowitz, P; Chua, M; Liu, Z; Diaz, LA; Rubenstein, DS. Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin. Am J Pathol., 2008 Dec, 173(6), 1628-36.
12. Lee, CL; Sit, WH; Jiang, PP; So, IW; Wan, JM. Polysaccharopeptide mimics ciclosporin-mediated Th1/Th2 cytokine balance for suppression of activated human T cell proliferation by MAPKp38 and STAT5 pathways. J Pharm Pharmacol., 2008 Nov, 60(11), 1491-9.
13. Chopra, P; Kanoje, V; Semwal, A; Ray, A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs, 2008 Oct, 17(10), 1411-25.
14. Yu, XJ; Li, CY; Dai, HY; Cai, DX; Wang, KY; Xu, YH; Chen, LM; Zhou, CL. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol., 2007 Dec, 83(3), 413-8.
15. Johansen, C; Moeller, K; Kragballe, K; Iversen, L. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol., 2007 Dec, 127(12), 2857-64.
16. Funding, AT; Johansen, C; Kragballe, K; Iversen, L. Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. J Invest Dermatol., 2007 Aug, 127(8), 2012-9.
17. Fischer, M; Harvima, IT; Carvalho, RF; Möller, C; Naukkarinen, A; Enblad, G; Nilsson, G. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest., 2006 Oct, 116(10), 2748-56.
18. Johansen, C; Kragballe, K; Westergaard, M; Henningsen, J; Kristiansen, K; Iversen, L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol., 2005 Jan, 152(1), 37-42.
19. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol., 2009 Feb 12.
20. Fijen, JW; Zijlstra, JG; De Boer, P; Spanjersberg, R; Tervaert, JW; Van Der Werf, TS; Ligtenberg, JJ; Tulleken, JE. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol., 2001 Apr, 124(1), 16-20.
21. Fijen, JW; Tulleken, JE; Kobold, AC; de Boer, P; van der Werf, TS; Ligtenberg, JJ; Spanjersberg, R; Zijlstra, JG. Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med., 2002 Apr, 30(4), 841-5.
22. Parasrampuria, DA; de Boer, P; Desai-Krieger, D; Chow, AT; Jones, CR. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol., 2003 Apr, 43(4), 406-13.
23. Ward, KW; Proksch, JW; Salyers, KL; Azzarano, LM; Morgan, JA; Roethke, TJ; McSurdy-Freed, JE; Levy, MA; Smith, BR. SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics. Xenobiotica, 2002 Mar, 32(3), 221-33.
24. Haddad, JJ. VX-745. Vertex Pharmaceuticals. Curr Opin Investig Drugs, 2001 Aug, 2(8), 1070-6.
25. Branger, J; van den Blink, B; Weijer, S; Madwed, J; Bos, CL; Gupta, A; Yong, CL; Polmar, SH; Olszyna, DP; Hack, CE; van Deventer, SJ; Peppelenbosch, MP; van der Poll, T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol., 2002 Apr 15, 168(8), 4070-7.
26. Branger, J; van den Blink, B; Weijer, S; Gupta, A; van Deventer, SJ; Hack, CE; Peppelenbosch, MP; van der Poll, T. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood, 2003 Jun 1, 101(11), 4446-8.
27. Nikas, SN; Drosos, AA. SCIO-469 Scios Inc. Curr Opin Investig Drugs, 2004 Nov, 5(11), 1205-12.
28. Dominguez, C; Powers, DA; Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel, 2005 Jul, 8(4), 421-30.
29. Adcock, IM; Chung, KF; Caramori, G; Ito, K. Kinase inhibitors and airway inflammation. Eur J Pharmacol., 2006 Mar 8, 533(1-3), 118-32.
30. Ding, C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr Opin Investig Drugs, 2006 Nov, 7(11), 1020-5.
31. Schreiber, S; Feagan, B; D'Haens, G; Colombel, JF; Geboes, K; Yurcov, M; Isakov, V; Golovenko, O; Bernstein, CN; Ludwig, D; Winter, T; Meier, U; Yong, C; Steffgen, J. BIRB 796 Study Group. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol., 2006 Mar, 4(3), 325-34.
32. Cohen, SB; Cheng, TT; Chindalore, V; Damjanov, N; Burgos-Vargas, R; Delora, P; Zimany, K; Travers, H; Caulfield, JP. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum., 2009 Feb, 60(2), 335-44.
33. Dent, P; Yacoub, A; Fisher, PB; Hagan, MP; Grant, S. MAPK pathways in radiation responses. Oncogene, 2003 22, 5885-5896.
34. Brautigam, VM; Frasier, C; Nikodemova, M; Watters, JJ. Purinergic receptor modulation of BV-2 microglial cell activity: Potential involvement of p38 MAP kinase and CREB. JNeuroimmunol., 2005 Sep, 166(1-2), 113-25.
35. Slomiany, BL; Slomiany, A. Porphyromonas gingivalis lipopolysaccharide interferes with salivary mucin synthesis through inducible nitric oxide synthase activation by ERK and p38 kinase. Biochem Biophys Res Commun., 2002 Oct 11, 297(5), 1149-53.
36. Morin, CI; Huot, J. Recent advances in stress signaling in cancer. Cancer Res., 2004 64, 1893-1898.
37. Hsu, S; Dickinson, DP; Qin, H; Borke, J; Ogbureke, K; Winger, JN; Walsh, DS; Bollag, WB; Stoppler, H; Sharawy, M; Schuster, G. Green tea polyphenols reduce autoimmune symptoms in a murine model for human Sjogren's syndrome and protect human salivary acinar cells from TNF-alpha-induced cytotoxicity. 2007. Autoimmunity, 40(2), 138-47.
38. Perdiguero, E; Ruiz-Bonilla, V; Serrano, AL; Muñoz-Cánoves, P. Genetic deficiency of p38alpha reveals its critical role in myoblast cell cycle exit: the p38alpha-JNK connection. Cell Cycle, 2007 Jun 1, 6(11), 1298-303.
39. Ventura, JJ; Tenbaum, S; Perdiguero, E; Huth, M; Guerra, C; Barbacid, M; Pasparakis, M; Nebreda, AR. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet., 2007 Jun, 39(6), 750-8.
40. Hui, L; Bakiri, L; Stepniak, E; Wagner, EF. p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle, 2007 Oct 15, 6(20), 2429-33.
41. Hui, L; Bakiri, L; Mairhorfer, A; Schweifer, N; Haslinger, C; Kenner, L; Komnenovic, V; Scheuch, H; Beug, H; Wagner, EF. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet, 2007 Jun, 39(6), 741-9.
42. Hsu, S; Yamamoto, T; Borke, J; Walsh, DS; Singh, B; Rao, S; Takaaki, K; Lapp, C; Lapp, D; Foster, E; Bollag, WB; Lewis, J; Wataha, J; Osaki, T; Schuster, G. Green tea polyphenol-induced epithelial cell terminal differentiation is associated with coordinated expression of p57/KIP2 and caspase 14. 2005. J Pharmacol Exp Ther., 312, 884-90.
43. Walsh, D; Borke, J; Singh, B; Do, N; Balagon, MV; Abalos, RM; Hsu, S. Psoriasis is characterized by altered epidermal expression of caspase 14, a novel regulator of keratinocyte terminal differentiation and barrier formation. Journal of Dermatological Science, 2005, Jan, 37(1), 61-3.
44. Hsu, S; Dickinson, D; Borke, J; Qin, H; Winger, J; Henna Pearl; Walsh, D; Bollag, WB; Wood, J; Schuster, G. Green tea polyphenols reduced the psoriasiform lesions and regulate caspase 14 by the mitogen-activated protein kinase pathways. Experimental Dermatology, 2007, 16(8), 678.
45. Lippens, S; Kockx, M; Denecker, G; Knaapen, M; Verheyen, A; Christiaen, R; Tschachler, E; Vandenabeele, P; Declercq, W. Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures. Am J Pathol., 2004 Sep, 165(3), 833-41.
46. Hsu, S. Green Tea and the Skin. Journal of the American Academy of Dermatology, 2005, 52(6), 1049-59.
47. Hsu, S; Dickinson, D; Qin, H; Lapp, C; Lapp, D; Borke, J; Walsh, DS; Bollag, WB; Stoppler, H; Yamamoto, T; Osakai, T; Schuster, G. Inhibition of Autoantigen Expression by Epigallocatechin-3-Gallate (the Major Constituent of Green Tea) in Normal Human Cells (2005) J. Pharmacol. Exp. Ther., 2005, 315, 805-811.
48. Hsu, S; Dickinson, D. Green Tea: A New Approach to Managing Oral manifestations of Sjogren's Syndrome and Skin Manifestations of Lupus. Journal of Biochemistry and Molecular Biology, 2006, 39, 229-39.
49. Gillespie, K; Kodani, I; Dickinson, DP; Ogbureke, KUE; Camba, AM; Wu, M; Looney, S; Chu, TC; Qin, H; Bisch, F; Sharawy, M; Schuster, G; Hsu, SD. Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease. Life Sciences, 2008. 83, 581-588.